On June 8, 2020 Eli Lilly and Company (NYSE:LLY) reported that it will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020 (Press release, Eli Lilly, JUN 8, 2020, View Source [SID1234560896]). Joshua Smiley, senior vice president and Lilly’s chief financial officer, will participate in a virtual fireside chat at 2:10 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s investor website at View Source A replay will be available for approximately 90 days.

On June 8, 2020 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported that Jeffrey Eisenberg, Chief Executive Officer of Xenetic, will present at the Virtual Investor Fireside Chat Series on Tuesday, June 16, 2020 at 12:00 PM ET (Press release, Xenetic Biosciences, JUN 8, 2020, View Source [SID1234560895]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live video webcast of the fireside chat will be available on the IR Calendar page of the Investors section of the Company’s website (xeneticbio.com). Immediately following the fireside chat, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for one year.

To schedule a one-on-one call with management, please submit a request through the conference website vifiresidechat.com, or contact the conference at [email protected]. For more information about the event, please visit vifiresidechat.com.

On June 8, 2020 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, reported that the Company’s VP of Business Development, Dr. Sari Fishman, is conducting one-on-one meetings with pharmaceutical companies for potential distribution and partnerships for the Company’s drug candidates, Piclidenoson and Namodenoson, at the BIO International Convention 2020 which is taking place digitally on June 8-12, 2020 (Press release, Can-Fite BioPharma, JUN 8, 2020, View Source [SID1234560894]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Namodenoson’s highly encouraging Phase II data showing it substantially resolved all cases of NASH, in addition to the drug’s advancement towards a global pivotal Phase III study in liver cancer underscores its value for potential partnership agreements. Likewise, we expect interim data for Piclidenoson on Phase III studies in psoriasis and rheumatoid arthritis by the end of this year. With our advanced stage clinical pipeline, this is very opportune timing for us to engage in discussions with potential pharma partners seeking safe and effective drugs for autoimmune and liver diseases," stated Can-Fite CEO Dr. Pnina Fishman.

Can-Fite currently has out-licensing agreements for its Namodenoson and Piclidenoson drug candidates in several territories and has received approximately $18 million in upfront and milestone payments to date.

On June 4, 2020 EpiVax, Inc. ("EpiVax") a Rhode Island-based company and recognized leader in the field in the field of immunogenicity assessment reported it has licensed its advanced in silico toolkit for biologics immunogenicity screening, ISPRI, to AbCellera Biologics Inc. ("AbCellera") (Press release, EpiVax, JUN 8, 2020, View Source [SID1234560893]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The ISPRI toolkit allows researchers to assess and mitigate the safety and efficacy of biologic candidates in real-time. The platform enables not only the identification of T cell epitopes, but also the characterization of predicted T cell response to biologics. This ability to differentiate between inflammatory and regulatory T cell immune responses utilizing computational tools is unique to EpiVax’s platforms, ISPRI and iVAX.

AbCellera, a leading biotech company in therapeutic antibody discovery from natural immune systems, plans to utilize the ISPRI toolkit to support lead candidate selection in their antibody discovery programs.

"We are pleased to enter into this relationship with EpiVax. EpiVax is a recognized leader in the field and the addition of ISPRI to AbCellera’s discovery and engineering platforms will accelerate the advancement of promising therapeutics to clinical development" said Kevin Heyries, Head of Business Development at AbCellera.

Annie De Groot, MD, CEO/CSO of EpiVax said, "We are pleased to see AbCellera join the roster of leading pharmaceutical companies that are using ISPRI to assess preclinical immunogenicity."

On June 8, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported that Avi Oler, Senior Vice President, Corporate Development, will present at BIO Digital 2020, being held virtually June 8 – 12, 2020 (Press release, Onconova, JUN 8, 2020, View Source [SID1234560892]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Oler will provide an overview of the Company’s corporate development objectives and upcoming milestones for its lead candidate rigosertib and its oncology product candidate pipeline. The presentation will be available here for viewing on-demand.

Mr. Oler will be available for virtual meetings throughout BIO Digital. To arrange a meeting, please visit the BIO One-on-One Partnering webpage.